Biocryst Pharmaceuticals (BCRX) Change in Acquisitions & Divestments (2010 - 2026)

Biocryst Pharmaceuticals has reported Change in Acquisitions & Divestments for 17 years, with the latest figure at $221.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 191.1% year-over-year to $221.2 million; the trailing twelve-month figure through Mar 2026 stood at $401.9 million (up 43.8% YoY), and the FY2025 full-year result was $256.6 million, down 19.92% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $221.2 million, up from $49.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $221.2 million in Q1 2026, with the low at $4.0 million in Q2 2022.
• Historically, Change in Acquisitions & Divestments has averaged $81.3 million across 5 years, with a median of $69.7 million in 2023.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments surged 1558.12% — and 2024, when it plunged 76.03%.
• Biocryst Pharmaceuticals' Change in Acquisitions & Divestments stood at $77.7 million in 2022, then surged by 66.02% to $129.1 million in 2023, then tumbled by 55.06% to $58.0 million in 2024, then retreated by 15.52% to $49.0 million in 2025, then soared by 351.5% to $221.2 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $221.2 million (Q1 2026), $49.0 million (Q4 2025), and $73.0 million (Q3 2025), per Business Quant data.